Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy

Muscle and Nerve

Volumn 41, Issue 2, 2010, Pages 197-201

  Shieh, Kenneth ^a   Gilchrist, James M ^b   Promrat, Kittichai ^a,c  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Fatty liver; Insulin resistance; Myotonic dystrophy; Nonalcoholic fatty liver disease; Steatohepatitis; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIET RESTRICTION; FEMALE; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FUNCTION TEST; MALE; METABOLIC SYNDROME X; MORBIDITY; MYOTONIC DYSTROPHY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; COHORT STUDIES; ELECTROMYOGRAPHY; FATTY LIVER; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERINSULINISM; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; OBESITY; PREDICTIVE VALUE OF TESTS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 76649111700     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21484     Document Type: Article

References (33)

1. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008;28:339-350.
2. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-3014.
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
5. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
6. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91:4753-4761.
7. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.
8. Harper P. Myotonic dystrophy. Philadelphia: W.B. Saunders; 2001.
9. Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004;74:793-804.
10. Achiron A, Barak Y, Magal N, Shohat M, Cohen M, Barar R, et al. Abnormal liver test results in myotonic dystrophy. J Clin Gastroenterol 1998;26:292-295.
11. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 1992;68:799-808.
12. Wheeler TM. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics 2008;5:592-600.
13. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 2006;29:259-277.
14. Cooper TA. A reversal of misfortune for myotonic dystrophy? N Engl J Med 2006;355:1825-1827.
15. Moxley RT, Corbett AJ, Minaker KL, Rowe JW. Whole body insulin resistance in myotonic dystrophy. Ann Neurol 1984;15:157-162.
16. Moxley RT III, Griggs RC, Goldblatt D, VanGelder V, Herr BE, Thiel R. Decreased insulin sensitivity of forearm muscle in myotonic dystrophy. J Clin Invest 1978;62:857-867.
17. Morrone A, Pegoraro E, Angelini C, Zammarchi E, Marconi G, Hoffman EP. RNA metabolism in myotonic dystrophy: patient muscle shows decreased insulin receptor RNA and protein consistent with abnormal insulin resistance. J Clin Invest 1997;99:1691-1698.
18. Krentz AJ, Clark PM, Cox L, Williams AC, Nattrass M. Hyperproinsulinaemia in patients with myotonic dystrophy. Diabetologia 1992;35: 1170-1172.
19. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998;158:1789-1795.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
22. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
23. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.
24. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-967.
25. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005;329:111-116.
26. Al-Osaimi AM, Berg CL, Caldwell SH. Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. Hepatology 2005;41:943.
27. Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007;102:2716-2717.
28. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001;29:40-47.
29. Paul S, Dansithong W, Kim D, Rossi J, Webster NJ, Comai L, et al. Interaction of muscleblind, CUG-BP1 and hnRNP H proteins in DM1-associated aberrant IR splicing. EMBO J 2006;25:4271-4283.
30. Johansson A, Andrew R, Forsberg H, Cederquist K, Walker BR, Olsson T. Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy. J Clin Endocrinol Metab 2001;86:4276-4283.
31. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, et al. Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004;101:7088-7093.
32. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
33. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9-13.